人表皮生长因子受体2靶向的乳腺癌正电子发射断层显像/单光子发射计算机断层显像：对肿瘤治疗和预后至关重要的生物标志物的无创测量
Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis.
作者信息
Henry Kelly E, Ulaner Gary A, Lewis Jason S
机构信息
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Radiology, Weill Cornell Medical College, New York, NY 10065, USA.
出版信息
PET Clin. 2017 Jul;12(3):269-288. doi: 10.1016/j.cpet.2017.02.001.
Abstract
Increased human epidermal growth factor receptor 2 (HER2) expression is a hallmark of aggressive breast cancer. Imaging modalities have the potential to diagnose HER2-positive breast cancer and detect distant metastases. The heterogeneity of HER2 expression between primary and metastatic disease sites limits the value of tumor biopsies. Molecular imaging is a noninvasive tool to assess HER2-positive primary lesions and metastases. Radiolabeled antibodies, antibody fragments, and affibody molecules devise a reliable and quantitative method for detecting HER2-positive cancer using PET. HER2-targeted PET imaging is a valuable clinical tool with respect to both the care and maintenance of patients with breast cancer.
摘要
人表皮生长因子受体2（HER2）表达增加是侵袭性乳腺癌的一个标志。成像方式有潜力诊断HER2阳性乳腺癌并检测远处转移。原发性和转移性疾病部位之间HER2表达的异质性限制了肿瘤活检的价值。分子成像是评估HER2阳性原发性病变和转移灶的一种非侵入性工具。放射性标记的抗体、抗体片段和亲和体分子设计了一种使用PET检测HER2阳性癌症的可靠且定量的方法。HER2靶向PET成像对于乳腺癌患者的护理和维持都是一种有价值的临床工具。
相似文献
1
Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis.人表皮生长因子受体2靶向的乳腺癌正电子发射断层显像/单光子发射计算机断层显像：对肿瘤治疗和预后至关重要的生物标志物的无创测量
PET Clin. 2017 Jul;12(3):269-288. doi: 10.1016/j.cpet.2017.02.001.
2
First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule.使用¹¹¹铟标记的ABY-025亲和分子对乳腺癌转移灶中HER2表达进行的首次人体分子成像。
J Nucl Med. 2014 May;55(5):730-5. doi: 10.2967/jnumed.113.131243. Epub 2014 Mar 24.
3
Preparation and and Characterization of the Tumor-specific Antigen-derived Peptide as a Potential Candidate for Targeting Human Epidermal Growth Factor Receptor 2-positive Breast Carcinomas.肿瘤特异性抗原衍生肽作为靶向人表皮生长因子受体2阳性乳腺癌潜在候选物的制备与表征
Anticancer Res. 2018 May;38(5):2823-2830. doi: 10.21873/anticanres.12527.
4
Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer.人表皮生长因子受体2和人表皮生长因子受体3成像在乳腺癌中的临床潜力
PET Clin. 2018 Jul;13(3):423-435. doi: 10.1016/j.cpet.2018.02.010.
5
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT.使用[68Ga]ABY-025 亲和体PET/CT测量转移性乳腺癌中的HER2受体表达
Theranostics. 2016 Jan 1;6(2):262-71. doi: 10.7150/thno.13502. eCollection 2016.
6
18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.新辅助治疗两个周期后的18F-氟脱氧葡萄糖（FDG）PET/CT可预测HER2阴性乳腺癌的反应，但对HER2阳性乳腺癌无效。
Oncotarget. 2015 Oct 6;6(30):29388-95. doi: 10.18632/oncotarget.5001.
7
Development of the Tumor-Specific Antigen-Derived Synthetic Peptides as Potential Candidates for Targeting Breast and Other Possible Human Carcinomas.肿瘤特异性抗原衍生合成肽作为靶向乳腺癌和其他可能人类癌的潜在候选物的开发。
Molecules. 2019 Aug 29;24(17):3142. doi: 10.3390/molecules24173142.
8
89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.89Zr-曲妥珠单抗 PET/CT 检测人表皮生长因子受体 2 阴性原发性乳腺癌患者中人类表皮生长因子受体 2 阳性转移灶
Clin Nucl Med. 2017 Dec;42(12):912-917. doi: 10.1097/RLU.0000000000001820.
9
Development of Tc-radiolabeled nanosilica for targeted detection of HER2-positive breast cancer.用于靶向检测HER2阳性乳腺癌的锝标记纳米二氧化硅的研发
Int J Nanomedicine. 2017 May 2;12:3447-3461. doi: 10.2147/IJN.S129720. eCollection 2017.
10
Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT.使用亲和体分子ABY-025结合正电子发射断层扫描（PET）和单光子发射计算机断层扫描（SPECT）对乳腺癌转移灶中HER2表达进行简化评估的图像内参考。
Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1337-1346. doi: 10.1007/s00259-017-3650-3. Epub 2017 Mar 6.
引用本文的文献
1
Radiolabeled HER2-targeted molecular probes in breast cancer imaging: current knowledge and future prospective.用于乳腺癌成像的放射性标记HER2靶向分子探针：当前认知与未来展望
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan 3. doi: 10.1007/s00210-024-03691-7.
2
Changes in expression of breast cancer tumor biomarkers between primary tumors and corresponding metastatic sites: common patterns and relationships with survival.原发肿瘤与相应转移部位之间乳腺癌肿瘤标志物表达的变化：常见模式及其与生存的关系。
Breast Cancer Res Treat. 2024 Sep;207(2):373-382. doi: 10.1007/s10549-024-07368-w. Epub 2024 May 23.
3
PET/CT and SPECT/CT Imaging of HER2-Positive Breast Cancer.人表皮生长因子受体2阳性乳腺癌的正电子发射断层显像/计算机断层扫描及单光子发射计算机断层显像/计算机断层扫描成像
J Clin Med. 2023 Jul 25;12(15):4882. doi: 10.3390/jcm12154882.
4
Efficacy of a HER2-Targeted Thorium-227 Conjugate in a HER2-Positive Breast Cancer Bone Metastasis Model.一种HER2靶向钍-227偶联物在HER2阳性乳腺癌骨转移模型中的疗效
Cancers (Basel). 2023 Jun 29;15(13):3419. doi: 10.3390/cancers15133419.
5
Direct Intra-Patient Comparison of Scaffold Protein-Based Tracers, [Tc]Tc-ADAPT6 and [Tc]Tc-(HE)-G3, for Imaging of HER2-Positive Breast Cancer.基于支架蛋白的示踪剂[锝]Tc-ADAPT6和[锝]Tc-(HE)-G3在HER2阳性乳腺癌成像中的直接患者体内比较
Cancers (Basel). 2023 Jun 11;15(12):3149. doi: 10.3390/cancers15123149.
6
Biparatopic anti-HER2 drug radioconjugates as breast cancer theranostics.双靶点抗 HER2 药物偶联物用于乳腺癌治疗学。
Br J Cancer. 2023 Jul;129(1):153-162. doi: 10.1038/s41416-023-02272-4. Epub 2023 Apr 24.
7
Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions.脑转移瘤：神经肿瘤学会（SNO）关于当前管理和未来方向的共识综述。
Neuro Oncol. 2022 Oct 3;24(10):1613-1646. doi: 10.1093/neuonc/noac118.
8
Intratumoral in vivo staging of breast cancer by multi-tracer PET and advanced analysis.通过多示踪剂PET和高级分析对乳腺癌进行瘤内体内分期
NPJ Breast Cancer. 2022 Mar 24;8(1):41. doi: 10.1038/s41523-022-00398-x.
9
Automated light-induced synthesis of Zr-radiolabeled antibodies for immuno-positron emission tomography.自动光诱导合成 Zr 放射性标记抗体用于免疫正电子发射断层扫描。
Sci Rep. 2022 Jan 13;12(1):668. doi: 10.1038/s41598-021-04626-5.
10
A Unified Transcriptional, Pharmacogenomic, and Gene Dependency Approach to Decipher the Biology, Diagnostic Markers, and Therapeutic Targets Associated with Prostate Cancer Metastasis.一种统一的转录、药物基因组学和基因依赖性方法，用于解读与前列腺癌转移相关的生物学、诊断标志物和治疗靶点。
Cancers (Basel). 2021 Oct 14;13(20):5158. doi: 10.3390/cancers13205158.
本文引用的文献
1
Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT.使用89Zr-曲妥珠单抗PET/CT检测HER2阴性原发性乳腺癌患者中的HER2阳性转移灶。
J Nucl Med. 2016 Oct;57(10):1523-1528. doi: 10.2967/jnumed.115.172031. Epub 2016 May 5.
2
(18)F-nanobody for PET imaging of HER2 overexpressing tumors.用于HER2过表达肿瘤PET成像的F型纳米抗体
Nucl Med Biol. 2016 Apr;43(4):247-52. doi: 10.1016/j.nucmedbio.2016.01.002. Epub 2016 Jan 23.
3
Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients.抗HER2亲和体分子68Ga-ABY-025在乳腺癌患者中的生物分布与辐射剂量测定
J Nucl Med. 2016 Jun;57(6):867-71. doi: 10.2967/jnumed.115.169342. Epub 2016 Feb 9.
4
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT.使用[68Ga]ABY-025 亲和体PET/CT测量转移性乳腺癌中的HER2受体表达
Theranostics. 2016 Jan 1;6(2):262-71. doi: 10.7150/thno.13502. eCollection 2016.
5
Molecular Imaging of Biomarkers in Breast Cancer.乳腺癌生物标志物的分子成像
J Nucl Med. 2016 Feb;57 Suppl 1(Suppl 1):53S-9S. doi: 10.2967/jnumed.115.157909.
6
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.分子成像作为一种工具，用于研究晚期HER2阳性乳腺癌的异质性，并预测接受曲妥珠单抗-恩杂鲁胺（T-DM1）治疗的患者预后：ZEPHIR试验。
Ann Oncol. 2016 Apr;27(4):619-24. doi: 10.1093/annonc/mdv577. Epub 2015 Nov 23.
7
Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.68Ga-HER2-Nanobody 的 I 期研究用于评估乳腺癌中 HER2 表达的 PET/CT。
J Nucl Med. 2016 Jan;57(1):27-33. doi: 10.2967/jnumed.115.162024. Epub 2015 Oct 8.
8
Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.曲妥珠单抗辅助治疗人表皮生长因子受体2阳性且肿瘤≤2 cm的早期乳腺癌患者的疗效：曲妥珠单抗随机试验的荟萃分析
J Clin Oncol. 2015 Aug 20;33(24):2600-8. doi: 10.1200/JCO.2015.60.8620. Epub 2015 Jun 22.
9
(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients.（64）Cu-DOTA-曲妥珠单抗PET成像与HER2阳性乳腺癌患者脑转移灶的HER2特异性
EJNMMI Res. 2015 Mar 12;5:8. doi: 10.1186/s13550-015-0082-6. eCollection 2015.
10
Antibody positron emission tomography imaging in anticancer drug development.抗体正电子发射断层扫描成像在抗癌药物开发中的应用。
J Clin Oncol. 2015 May 1;33(13):1491-504. doi: 10.1200/JCO.2014.57.8278. Epub 2015 Mar 16.
Zotero 插件